Compare Cassava Sciences Inc (FLNA) vs McDonald's Corp (MCD) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

McDonald's (MCD) trades at $230.88, down 0.68% on the day, with a bearish technical signal from moving averages. The company shows steady revenue growth, reaching $26.89B in 2025, and has consistently beaten EPS estimates in recent quarters. Recent news highlights a new global growth strategy, 'McDonald's NEXT', focusing on automation and improved customer experience to counter competitive pressures and attract diners.

The outlook is mixed: strong fundamentals and a 58.7% analyst buy rating support upside to the $284.70 consensus target, but technical weakness and inflation-driven cost pressures pose near-term risks. The stock offers value through its dividend and defensive profile, yet investors must weigh execution risks of the new strategy against its long-term growth potential.